Nuvation Bio CPO granted 748,130 stock options

Nuvation Bio Inc. reported that its Chief People Officer, Markel Stacy, was granted a stock option covering 748,130 shares of Class A common stock on February 27, 2026.

Rhea-AI Filing Summary

Nuvation Bio Inc. reported that its Chief People Officer, Markel Stacy, was granted a stock option covering 748,130 shares of Class A common stock on February 27, 2026. The option vests 25% on the one-year anniversary of February 27, 2026 and then monthly over the following 36 months, contingent on her continued service.

After this grant, Stacy holds 748,130 stock options and 32,591 shares of Class A common stock directly, including 3,000 shares acquired on November 19, 2025 under the company’s 2021 Employee Stock Purchase Plan.

Insider Trade Summary

Grant/Award: 748,130 shares

Grant/Award 2 txns

Insider Markel Stacy

Role CHIEF PEOPLE OFFICER

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	748,130	$0.00	$0.00
holding	Class A Common Stock	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 748,130 contracts (Direct); Class A Common Stock — 32,591 shares (Direct)

Footnotes (2)

1. F1. Includes 3,000 shares acquired on November 19, 2025 under the Issuer's 2021 Employee Stock Purchase Plan.
2. F2. Option vests as to 25% on the one year anniversary of 2/27/2026, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date.

FAQ

What did Nuvation Bio (NUVB) disclose about Markel Stacy’s latest Form 4?

Nuvation Bio reported a new equity award to Chief People Officer Markel Stacy. She received a stock option for 748,130 shares on February 27, 2026, with vesting tied to continued service over four years.

How many stock options did Nuvation Bio’s Chief People Officer receive?

Markel Stacy was granted options on 748,130 shares of Nuvation Bio Class A common stock. This grant was recorded on February 27, 2026 and represents a significant component of her long-term equity compensation package.

What is the vesting schedule for Markel Stacy’s new NUVB stock options?

The option vests over four years, with 25% vesting on the one-year anniversary of February 27, 2026, and the remaining shares vesting monthly over the next 36 months, subject to her continuous service.

How many Nuvation Bio common shares does Markel Stacy now own directly?

Markel Stacy directly holds 32,591 Class A common shares following the reported transactions. This total includes 3,000 shares acquired on November 19, 2025 under Nuvation Bio’s 2021 Employee Stock Purchase Plan.

Does the Form 4 show any Nuvation Bio insider stock sales by Markel Stacy?

The reported activity reflects an equity award, not a sale. The Form 4 shows a grant of stock options to Markel Stacy and updated direct ownership of common shares, with no sale transactions indicated.

What role does Markel Stacy hold at Nuvation Bio (NUVB)?

Markel Stacy serves as Nuvation Bio’s Chief People Officer. The Form 4 filing details a large stock option grant and her direct holdings of Class A common shares as part of her compensation and ownership profile.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/03/2026 - 07:59 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Markel Stacy

(Last) (First) (Middle)

C/O NUVATION BIO INC.

1500 BROADWAY, SUITE 1401

(Street)

NEW YORK NY 10036

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Nuvation Bio Inc. [ NUVB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF PEOPLE OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock								32,591(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$5.91	02/27/2026		A		748,130		(2)	02/26/2036	Class A Common Stock	748,130	$0	748,130	D

Explanation of Responses:

1. Includes 3,000 shares acquired on November 19, 2025 under the Issuer's 2021 Employee Stock Purchase Plan.

2. Option vests as to 25% on the one year anniversary of 2/27/2026, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date.

	/s/ Stephen Dang, Attorney-in-Fact	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.